CRISM Therapeutics (LON:CRTX) Posts Earnings Results

CRISM Therapeutics (LON:CRTX) released its quarterly earnings data on Friday. The company reported GBX (0.05) earnings per share for the quarter, Digital Look Earnings reports.

CRISM Therapeutics Price Performance

LON CRTX opened at GBX 9.50 on Friday. CRISM Therapeutics has a 1-year low of GBX 8 and a 1-year high of GBX 23. The business’s fifty day moving average price is GBX 11.44 and its 200-day moving average price is GBX 11.65. The stock has a market capitalization of £5.15 million, a price-to-earnings ratio of -2.16 and a beta of 0.58.

CRISM Therapeutics Company Profile

CRISM Therapeutics Corporation is clinical stage company, having developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.

ChemoSeed, CRISM’s lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin.